鲁索替尼乳膏联合窄谱中波紫外线治疗白癜风
这项探索性2期研究评估了鲁索替尼乳膏联合窄谱中波紫外线(NB-UVB)治疗非节段性白癜风的疗效与安全性。55例患者先接受1.5%鲁索替尼乳膏单药治疗12周,其中35例T-VASI改善不足25%者加用NB-UVB至48周,T-VASI平均改善从-7.9%提升至-50.4%,联合治疗耐受良好。
要点
- 12周单药治疗未达T-VASI25者加用NB-UVB可显著改善复色。
- 48周时T-VASI50和T-VASI75分别为57.7%和19.2%。
- 鲁索替尼乳膏联合NB-UVB耐受良好,无新安全性问题。
核心结论
- 12周鲁索替尼乳膏单药治疗未达T-VASI25的白癜风患者,加用NB-UVB至48周可获得有意义的复色改善。
- 联合治疗耐受良好,未观察到新的安全性问题。
研究设计与样本
- 探索性2期研究,纳入55例年龄≥12岁、非节段性白癜风且脱色面积≤10%体表面积的患者。
- 患者先接受1.5%鲁索替尼乳膏每日两次单药治疗12周,T-VASI改善<25%者加用NB-UVB至48周。
- 主要终点为第48周T-VASI较基线变化,次要终点包括其他疗效、药代动力学和安全性评估。
主要发现
- 第12周时,35/55例(63.6%)患者T-VASI改善<25%并加用NB-UVB。
- 加用NB-UVB的35例患者中,T-VASI平均百分比变化从第12周的-7.9%(n=35)改善至第48周的-50.4%(n=26)。
- 第48周时,T-VASI50和T-VASI75分别从第12周的0%增至57.7%(15/26)和19.2%(5/26)。
关键数值与推荐
- T-VASI改善<25%定义为<T-VASI25,作为第12周加用NB-UVB的阈值。
- 主要终点为第48周T-VASI较基线变化。
临床怎么用
- 对于鲁索替尼乳膏单药治疗12周复色不佳的白癜风患者,可考虑联合NB-UVB治疗。
- 联合治疗前应评估患者12周时的T-VASI改善程度,以识别可能获益人群。
局限性
- 本研究为探索性2期研究,样本量较小(55例)。
- 第48周时部分患者数据缺失(n=26),可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib cream and narrow-band UVB (NB-UVB) phototherapy independently promote repigmentation in patients with vitiligo. This exploratory phase 2 study evaluated the efficacy and safety of adding NB-UVB to ruxolitinib cream therapy. Patients (aged ≥12 years) with nonsegmental vitiligo and depigmented areas ≤10% total body surface area applied 1.5% ruxolitinib cream monotherapy twice daily to depigmented areas. At week 12, patients achieving <25% improvement from baseline in total Vitiligo Area Scoring Index (T-VASI) (denoted as <T-VASI25) were eligible to add NB-UVB through week 48; patients achieving T-VASI25 or unable to initiate NB-UVB continued ruxolitinib cream monotherapy. Primary endpoint was T-VASI change from baseline at week 48; secondary endpoints included additional efficacy, pharmacokinetic, and safety assessments. This study enrolled 55 patients. At week 12, 35 of 55 (63.6%) patients had <T-VASI25 and added NB-UVB; mean percentage change from baseline in T-VASI improved from -7.9% at week 12 (n = 35) to -50.4% at week 48 (n = 26). T-VASI50 and T-VASI75 increased from 0% at week 12 to 57.7% (15 of 26) and 19.2% (5 of 26), respectively, at week 48. Ruxolitinib cream was well tolerated with or without NB-UVB. Patients with <T-VASI25 at week 12 experienced meaningful improvements in repigmentation with NB-UVB plus ruxolitinib cream combination therapy through week 48, with no new safety concerns.
引用
- Pandya AG, Lynde CW, Shayesteh Alam M, et al. Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo. J Invest Dermatol. 2025. PMID: 41386328. doi:10.1016/j.jid.2025.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。